Medical Guideline: Rivaroxaban (Xarelto®), Apixaban (Eliquis®), Edoxaban (Savaysa®): Factor Xa Inhibitors- Reversal Treatment for Bleeding

Brief Description: The guideline aims to provide recommendations for managing minor, major, and life-threatening bleeds in patients on factor Xa inhibitors. There is no pharmacologic antidote for factor Xa inhibitors, and treatment of bleeding remains empirical.


*For academic/non-profit pricing, or to customize this guideline before licensing, please contact

Price Negotiable

There may be various licensing options available for this product. Please contact